CPRX
Live News • 57m
Catalyst Pharmaceuticals Merger With Angelini Pharma Advances After Shareholder Approval Catalyst Pharmaceuticals stockholders approved the proposed merger with Angelini Pharma, clearing the way for Catalyst to become a wholly owned subsidiary of Angelini Pharma, with final voting results to be released after certification.
A separate, non-binding advisory proposal on compensation related to the merger did not receive stockholder approval, but this was not required to close the transaction and no adjournment vote was needed.
Catalyst Pharmaceuticals shares trade at $31.47, with the stock up 35.9% year to date.
This shareholder approval removes a key procedural hurdle for the deal and points to an ownership and governance shift at Catalyst Pharmaceuticals. At the same time, the failed advisory vote on compensation highlights some investor sensitivity around deal-related pay structures. Announcement • Jul 09
Catalyst Pharmaceuticals, Inc. Announces Board Changes Catalyst Pharmaceuticals, Inc. at its special meeting of its stockholders held on July 8, 2026 adopted the Merger Agreement. Company announced that In connection with the anticipated consummation of the merger and as contemplated by the merger agreement, each of the directors of the company (Patrick J. McEnany; Richard J. Daly; Daniel J. Curran, M.D.; Donald A. Denkhaus; Molly Harper; Tamar Thompson; and David S. Tierney, M.D.) indicated their intention to resign as a member of the board of directors of the company and any committee thereof, as applicable, conditioned upon and effective as of the effective time of the merger. These anticipated resignations were not a result of any disagreement between the company and the directors on any matter relating to the company's operations, policies or practices. Announcement • Jul 01
Santhera Pharmaceuticals Notes Topline Results from Catalyst Pharmaceuticals Phase 1 Clinical Study of AGAMREE Santhera Pharmaceuticals noted topline results from a two-part Phase 1 clinical study of AGAMREE conducted by its North American licensing partner, Catalyst Pharmaceuticals, Inc. The study suggests that AGAMREE delivers glucocorticoid and anti-inflammatory activity, while avoiding significant immunosuppressive effects, supporting its potential use as a treatment across a broad range of chronic inflammatory rare diseases. The study, conducted in healthy adult volunteers, evaluated equipotency between deflazacort and AGAMREE and assessed the clinical immunosuppressive potential of AGAMREE across ascending doses. In part A, both AGAMREE and deflazacort demonstrated expected on-target glucocorticoid receptor activity and comparable cortisol suppression at clinical doses, with AGAMREE showing less pronounced immunosuppressive biomarker effects, consistent with the currently labelled dosing of AGAMREE in the treatment of Duchenne muscular dystrophy (DMD). Part B demonstrated that clinically relevant immunosuppressive effects were observed only at the highest dose level, above currently approved AGAMREE dosing. No relevant immunosuppressive effects were observed at lower dose levels. Under an exclusive license agreement entered into in 2023, Catalyst holds commercialization rights to AGAMREE in North America for DMD and all potential future indications, while Santhera retains a right of first negotiation for any rights outside North America relating to new indications. Under the terms of the license agreement, Santhera is eligible to receive sales-based milestone payments as well as royalties on net sales across all commercialized indications. AGAMREE is a dissociative corticosteroid approved for the treatment of Duchenne muscular dystrophy (DMD). It binds selectively to the glucocorticoid receptor and triggers anti-inflammatory activity through inhibition of NF-?B-mediated gene transcription, while inducing reduced transactivation of other genes. AGAMREE is not a substrate for 11-ß-hydroxysteroid dehydrogenase (11ß-HSD) enzymes, which are involved in the local amplification of glucocorticoid activity in tissues and have been implicated in corticosteroid-associated toxicity. This pharmacological profile is the basis for its classification as a dissociative corticosteroid, designed to preserve anti-inflammatory efficacy while reducing the systemic effects associated with long-term conventional corticosteroid therapy. In the pivotal Phase 2b VISION-DMD study, AGAMREE met its primary endpoint, demonstrating a statistically significant improvement in Time to Stand (TTSTAND) velocity versus placebo at 24 weeks (p = 0.002). The most commonly reported adverse reactions were cushingoid features, vomiting, weight increase, increased appetite, and irritability; most were mild to moderate in severity. Long-term data from up to eight years of AGAMREE treatment were presented at the Muscular Dystrophy Association Clinical & Scientific Conference in March 2026. In propensity-matched analyses, AGAMREE demonstrated durable efficacy comparable to standard-of-care corticosteroids and a differentiated safety profile: a lower incidence of vertebral fractures versus deflazacort-treated cohorts (8.1% vs 41.9%; p = 0.0082); maintained a normal growth trajectory with a mean height advantage of 12.17 cm versus conventional corticosteroids (p < 0.0001), and a lower incidence of cataracts versus deflazacort (p = 0.015), with no observed cases of glaucoma. This medicinal product is subject to additional monitoring. Healthcare professionals are asked to report any suspected adverse reactions. 
